NPPA fixes ceiling price of two vaccines based on tender data from DoAHD

New Delhi, April 11, 2022:

The National Pharmaceutical Pricing Authority (NPPA) has fixed ceiling price of two vaccines which were announced as scheduled formulations of late, based on the latest price discovered by the Department of Animal Husbandry and Dairying (DoAHD) as the market-based data was not available.

The Authority has declared foot and mouth disease (Trivalent) oil adjuvant vaccine and Brucella Abortus (S19 strain) vaccine as scheduled formulation through orders on February 1, 2021. Following this, the ceiling prices of these vaccines are required to be fixed, but the market based data of the formulation was not available in AWACS PharmaTrac database.

In a recent meeting, the Authority noted that the foot and mouth disease (Trivalent) oil adjuvant vaccine was procured by DoAHD, Ministry of Fisheries, Animal Husbandry and Dairying through tender process and the Department has also provided the latest price discovered through tender process.

The latest price discovered through the tender process was also offered by the Department for the Brucella Abortus (S19) vaccine, live freeze dried.

The Authority deliberated upon the matter in detail and opined that the regulations of price of both the vaccines are essential in public interest so as to ensure availability of the vaccine in the country at affordable price.

Accordingly, it has decided to fix the ceiling price of foot and mouth disease vaccine at Rs. 14.82 per dose excluding goods and services tax, in which one dose is 2 ml. The price was arrived at by adding 16 per cent retailer margin on the L1 tender price of Rs. 6.39 per ml excluding GST. The price of Brucella Abortus vaccine was fixed at Rs. 10.16 per dose excluding GST (one dose is 2 ml after reconstitution), by adding 16 per cent retailer margin on the average tender price of Rs. 8.76 per dose excluding GST, provided by the DoAHD.

The Authority has fixed the ceiling price of framycetin 0.5 % cream as it has been declared as a scheduled formulation under the Drugs (Prices Control) Order, 2013.

The ceiling price of framycetin 0.5% ointment was fixed under the DPCO, 1995 and the NPPA opined that there is no significant difference between ‘cream’ and ‘ointment’ from the point of pharmacokinetics and pharmacodynamics and both are therapeutically the same.

Accordingly, it has approved the ceiling price at Rs. 1.07 per gram excluding GST. Framycetin is a topical amino-glycosides to treat bacterial infections in the eyes, ears and skin.

In the Authority’s 96th meeting held on March 24, 2022, under the chairmanship of NPPA chairman Kamlesh Kumar Pant, approved retail prices fixed for 56 new drugs under the DPCO, 2013. Pharmabiz